Universal Pneumococcus Vaccine Candidate, GEN-004, shows positive results in Phase 1 study
Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, announced yesterday positive top-line results from a Phase 1 study of GEN-004, an investigational More...